Erythropoietin Beta: Uses, Dosage, Side Effects & Brands | MedexInfo

Erythropoietin Beta

Rx

Generic NameErythropoietin Beta

Therapeutic ClassErythropoiesis-Stimulating Agent

RouteSC / IV

Max / 24hVaries by indication, usually 40,000 units/week SC

PregnancyUse only if benefit outweighs risk

Indications ▼

Anemia associated with chronic kidney disease (CKD) in adults and children

Prevention and treatment of chemotherapy-induced anemia in cancer patients

Anemia in patients undergoing elective, non-cardiac, non-vascular surgery to reduce need for transfusion

Anemia in critically ill patients (off-label in select cases)

Mechanism & Pharmacokinetics ▼

Mechanism: Recombinant human erythropoietin stimulates erythroid progenitor cells in the bone marrow, increasing red blood cell production and hemoglobin levels.

Pharmacokinetics: Administered SC or IV. SC absorption slower but longer duration. Half-life: 4–13 hours (SC), 6–8 hours (IV). Metabolized primarily in the liver and kidneys. Clearance increases with hematocrit.

Dosage & Administration ▼

Indication	Recommended Dose	Frequency
CKD (Adult, SC)	50–100 units/kg	3x/week
CKD (Adult, IV)	50–100 units/kg	3x/week
Chemotherapy-induced anemia	150 units/kg SC	3x/week or 40,000 units once weekly
Preoperative anemia (surgery)	300 units/kg SC	Weekly for 2–3 weeks prior to surgery

Note: Dose adjustment based on hemoglobin response; avoid rapid rise (>1 g/dL per 2 weeks).

Side Effects ▼

Hypertension

Headache, fatigue

Injection site reactions

Thromboembolic events (rare)

Seizures (rare)

Contraindications ▼

Uncontrolled hypertension

Hypersensitivity to erythropoietin or formulation components

Pure red cell aplasia due to anti-erythropoietin antibodies

Active malignancy where erythropoiesis stimulation may be harmful

Drug Interaction ▼

Androgens: may enhance erythropoietic response

Iron supplementation: required to maximize response

ACE inhibitors: may reduce response

Antihypertensives: monitor BP

Pregnancy & Lactation ▼

Use only if benefit outweighs risk (Category C)

Excretion in breast milk unknown; caution advised

Clinical / Research Summary ▼

Therapeutic Role: Stimulates RBC production in anemia due to CKD, chemotherapy, or surgery, reducing transfusion needs.

Clinical Effectiveness: Improves hemoglobin, reduces transfusion requirements, enhances patient quality of life.

Safety Profile: Well tolerated; main concerns are hypertension and thromboembolism. Hemoglobin monitoring is essential.

Current Research: Focus on optimal dosing, cardiovascular outcomes, and minimizing antibody-mediated pure red cell aplasia.

Patient Counseling Points ▼

Monitor blood pressure regularly

Report headache, dizziness, or visual changes

Do not shake or freeze the injection; store properly

Follow-up labs: hemoglobin, hematocrit, iron status

Storage & Handling ▼

Store at 2–8°C

Do not freeze

Protect from light

Keep out of reach of children

Brand Names (Bangladesh & Global) ▼

Bangladesh:

Recormon® 2000 IU/0.3 ml Recormon® 5000 IU/0.3 ml Recormon® 10000 IU/0.6 ml

Global:

NeoRecormon Eprex Binocrit

Medical Disclaimer: Educational purpose only. Not a substitute for professional medical advice.

Reference Hubs:

• Drug Class: Erythropoiesis-Stimulating Agents • Condition: Anemia • Condition: Chronic Kidney Disease